“We delivered a record quarter with broad-based strength across Distribution and Hyve, building on the momentum we have carried out of recent quarters. Our results reflect consistent execution against ...

Looking ahead to 2030, our model projects SLB could trade at an average price of $81.95, with a potential range between $61.46 and $102.43. This represents a potential 83.1% return from today's price.

Looking ahead to 2030, our model projects ZS could trade at an average price of $234.89, with a potential range between $176.17 and $293.61. This represents a potential 58.8% return from today's price ...

“Our first-quarter results reflect the benefits of our diversified business, our successful focus on operating efficiencies and our ongoing capital investment program. On a property-level basis, we ...

Novartis (NVS) Q1 2026 earnings: EPS $1.99 vs $2.07 est. (MISS by 3.7%). Revenue $13.11B vs $13.48B est. View earnings history, market reaction charts, and AI analysis.

“I am pleased to report a very strong start to the year with revenues and adjusted EPS exceeding expectations. Our revenues grew 15% organically, driven by our High Value Products Components business ...

The latest available figures from the U.S. Census Bureau show that more than 41 million Americans live below the poverty line, which for a single household, for example, means (in most of the country) ...

“American delivered record revenue in the first quarter, and we're on track for another record in the second quarter. This revenue momentum is the result of focus on our four commercial priorities — ...

“We delivered a strong first quarter, with earnings per share up 25% from the first quarter of 2025, driven by disciplined execution against our strategic priorities and continued momentum across the ...

“Fiscal 2025 was a year of disciplined execution and resilience, as we closed the year with a solid fourth quarter that delivered strong Adjusted EBITDA despite meaningful top-line pharmacy‑related ...

“The year is off to a good start. We delivered a solid first quarter, with strong momentum in our cold beverage portfolio and coffee results that tracked with our expectations, even as we navigated ...